These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26376844)

  • 1. Immunotherapies in Early and Advanced Renal Cell Cancer.
    Kasenda B; Larkin J; Gore M
    Prog Tumor Res; 2015; 42():1-10. PubMed ID: 26376844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current immunotherapeutic strategies in renal cell carcinoma.
    Amato RJ
    Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics.
    Bailey A; McDermott DF
    Cancer J; 2013; 19(4):348-52. PubMed ID: 23867517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines for melanoma and renal cell carcinoma.
    Kaufman HL
    Semin Oncol; 2012 Jun; 39(3):263-75. PubMed ID: 22595049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in renal cell cancer immunotherapy.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.
    Lenis AT; Donin NM; Johnson DC; Faiena I; Salmasi A; Drakaki A; Belldegrun A; Pantuck A; Chamie K
    J Urol; 2018 Jan; 199(1):43-52. PubMed ID: 28479237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
    Flippot R; Escudier B; Albiges L
    Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab in the treatment of advanced renal cell carcinoma.
    Arasaratnam M; Gurney H
    Future Oncol; 2018 Jul; 14(17):1679-1689. PubMed ID: 29460635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
    Atkins MB; Philips GK
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
    Wang Y; Wang XY; Subjeck JR; Shrikant PA; Kim HL
    Br J Cancer; 2011 Feb; 104(4):643-52. PubMed ID: 21285988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of Melanoma.
    Snyder A; Zamarin D; Wolchok JD
    Prog Tumor Res; 2015; 42():22-9. PubMed ID: 26376963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
    Bedke J; Stenzl A
    Expert Rev Anticancer Ther; 2013 Dec; 13(12):1399-408. PubMed ID: 24215158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-angiogenic therapy in renal cell cancer.
    Srinivasan R; Armstrong AJ; Dahut W; George DJ
    BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.